A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors

• Status: Completed
• Trial end date: 2021-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the administration of AdV-tk followed by valacyclovir in children with malignant glioma, including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), as well as recurrent ependymomas in combination with radiation therapy. The primary objective is to determine if this approach is safe and can be effectively delivered without disturbing standard therapy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Advantagene, Inc.; Candel Therapeutics, Inc.
• Collaborators: Boston Children's Hospital; Boston Children’s Hospital
• Treatments: Valacyclovir

Criteria

Inclusion Criteria:

• Patients must be 3 years of age or older

• Patients must be planning to undergo standard of care treatment with surgery and radiation therapy.

• Patients must have malignant glioma or recurrent ependymoma

• Tumor must be accessible for injection and must not be located in the brainstem or deep midbrain

• Performance Score: Karnofsky ≥60% if >10y/o, Lansky ≥60 if ≤10y/o

• Bone Marrow Function: Patients must have adequate bone marrow function defined as a peripheral absolute neutrophil count ≥ 1000/µl, platelet count ≥ 100,000/µl (transfusion independent) and hemoglobin ≥ 8.0 gm/dL

• Renal Function: Patients must have serum creatinine ≤ 1.5 times upper limit of institutional normal for age and/or GFR ≥ 70 mL/min/1.73 m2.

• Hepatic Function: Bilirubin ≤ 1.5 times institutional normal; SGPT (ALT) < 3 times institutional normal

• Serum electrolyte values (sodium, potassium, magnesium, calcium) must be checked prior to enrollment and clinically significant abnormalities corrected prior to surgery/AdV-tk injection

• Patients with seizure disorder may be enrolled if well controlled

• Signed informed consent according to institutional guidelines must be obtained

Exclusion Criteria:

• Prior or ongoing liver disease including known cirrhosis, hepatitis B or C infection but not to exclude patients with a distant history of resolved hepatitis A infection

• Patients on immunosuppressive drugs (with exception of corticosteroid)

• Known history of HIV or underlying immunodeficiency

• Patients with acute infections (viral, bacterial or fungal infections requiring therapy)

• Pregnant or breast-feeding patients. Female patients of childbearing age must have negative serum or urine pregnancy test within 1 week of beginning therapy

• Other serious co-morbid illness or compromised organ function

• No other investigational anti-tumor agents within 30 days prior to study entry or during active participation in the study (defined as from study entry until tumor progression)